Arkstone recognizes the critical need for a global approach to antimicrobial stewardship, considering the diverse healthcare landscapes and linguistic variations across different regions. GlobalGuidance allows Arkstone to bridge these gaps by providing OneChoice recommendations in any language and tailoring them to the unique drug formularies of specific regions or healthcare systems.
Dr. Ari Frenkel, Chief Science Officer at Arkstone, expressed his enthusiasm for the global impact of GlobalGuidance, stating, “The launch of GlobalGuidance signifies a pivotal moment in our commitment to combating antimicrobial resistance on a global scale. By delivering OneChoice recommendations in any language and tailoring them to specific regions, we are breaking down barriers and empowering healthcare professionals worldwide to make informed treatment decisions.”
The customized drug formularies, a hallmark of GlobalGuidance, are meticulously curated in collaboration with laboratories and healthcare providers. Arkstone ensures that the formularies accurately reflect the available drugs in each region, providing healthcare professionals with recommendations that consider local availability without limiting treatment options. This approach not only enhances the precision of treatment but also fosters a more comprehensive antimicrobial stewardship strategy.
Dr. Juan Carlos Gómez de la Torre, Director of Molecular Informatics at Arkstone, highlighted the collaborative effort behind GlobalGuidance, stating, “Our collaboration with labs and providers ensures that GlobalGuidance is not only linguistically accessible but also reflects the drug availability in each region. This ensures that healthcare professionals receive recommendations that are both accurate and contextually relevant.”
As Arkstone continues to pioneer advancements in infectious disease analysis and antimicrobial stewardship, the launch of GlobalGuidance marks a significant step towards achieving a global impact in the fight against antimicrobial resistance. The company remains dedicated to evidence-based information, continuous innovation, and improving patient outcomes worldwide.
Arkstone is committed to stem the global spread of antimicrobial resistance and the misuse of antibiotics by marrying advanced artificial intelligence with a deep understanding of infectious disease. Arkstone’s patent-pending OneChoice technology helps physicians practice precision-guided medicine through optimal treatment regimen recommendations. Additionally, the proprietary ArkScore system allows providers to compare antibiotics at a glance through an easy to understand visual score. Learn more at www.arkstonemedical.com or email info@arkstonemedical.com
###